Home/ Supplements/ Vitamin K/ Vitamin K 2

Vitamin K 2

product on market Capsule Signature Supplements Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Vitamin K2 is associated with supporting bone and cardiovascular health, while nattokinase is researched for its fibrinolytic properties. Evidence for these specific benefits is generally moderate, though overall evidence coverage for this formulation is limited. The profile maintains a high safety score.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Vitamin K 2
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Capsule(s)
Serving Size
50
Servings
Other Combinations
Product Type
50%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

200 mcg (150% DV)
1.7× RDA — within safe limits 275 studies (A:9, B:175)
200 mg
Market median: 100.0mg (70 products)

Other Ingredients

Cellulose Diatomaceous
Claims

Label Claims — Verification

Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Directions: For adults, take one (1) to two (2) capsules daily, preferably with a meal.

Warnings & Precautions

Do not take this product within 2 hours of taking medications or follow the advice of your health care providers. Warning: Pregnant or lactating women should consult a doctor before using any product. Consult doctor before use if you have, or have had, kidney disease, if you are on a magnesium-restricted diet or if you are taking any medications or remedies such as those to treat high blood pressure, heart medications, muscle relaxants or diuretics.

Discontinue use and consult your doctor if any adverse reactions occur, such as gastrointestinal discomfort or low blood pressure.

Not intended for use by persons under the age of 18. Keep out of reach of children.

Formulation Notes

No: chemical fillers or binders, artificial coloring, artificial flavor, preservatives, yeast, corn, milk or milk derivatives, lactose, salt, sodium, soy, sugar, gluten, starch or wheat.

From a GMP Facility

Helps body transport calcium Time release

Additional Information

Store in a dry place and avoid excessive heat.

Metadata

Product Details

DSLD Entry Date2025-08-22
Product TypeOther Combinations
FormCapsule
DSLD ID338979
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.